392 related articles for article (PubMed ID: 31284051)
21. Editorial: Improving responses to immunotherapy in glioblastoma multiforme.
McArdle SEB; Nagarajan D; Barish ME
Front Immunol; 2024; 15():1407930. PubMed ID: 38715607
[No Abstract] [Full Text] [Related]
22. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
[TBL] [Abstract][Full Text] [Related]
23. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
Batich KA; Swartz AM; Sampson JH
Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy for Brain Tumors: Where We Have Been, and Where Do We Go From Here?
Wang AF; Hsueh B; Choi BD; Gerstner ER; Dunn GP
Curr Treat Options Oncol; 2024 May; 25(5):628-643. PubMed ID: 38649630
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of immunomodulation in human glioblastoma.
Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
[TBL] [Abstract][Full Text] [Related]
26. Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.
Yang L; Guo G; Niu XY; Liu J
Biomed Res Int; 2015; 2015():717530. PubMed ID: 26167495
[TBL] [Abstract][Full Text] [Related]
27. Cold atmospheric plasma induces silver nanoparticle uptake, oxidative dissolution and enhanced cytotoxicity in glioblastoma multiforme cells.
Manaloto E; Gowen AA; Lesniak A; He Z; Casey A; Cullen PJ; Curtin JF
Arch Biochem Biophys; 2020 Aug; 689():108462. PubMed ID: 32590068
[TBL] [Abstract][Full Text] [Related]
28. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.
Bregy A; Wong TM; Shah AH; Goldberg JM; Komotar RJ
Cancer Treat Rev; 2013 Dec; 39(8):891-907. PubMed ID: 23790634
[TBL] [Abstract][Full Text] [Related]
29. Harnessing the immune system in glioblastoma.
Brown NF; Carter TJ; Ottaviani D; Mulholland P
Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
[TBL] [Abstract][Full Text] [Related]
30. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy for brain tumors: basic developments and clinical implementation.
Assi H; Candolfi M; Baker G; Mineharu Y; Lowenstein PR; Castro MG
Neurosci Lett; 2012 Oct; 527(2):71-7. PubMed ID: 22906921
[TBL] [Abstract][Full Text] [Related]
32. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
Zhang B; Shen R; Cheng S; Feng L
Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
[TBL] [Abstract][Full Text] [Related]
33. DCVax®-L--developed by Northwest Biotherapeutics.
Polyzoidis S; Ashkan K
Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
[TBL] [Abstract][Full Text] [Related]
34. Glioblastoma stem cells and stem cell-targeting immunotherapies.
Esparza R; Azad TD; Feroze AH; Mitra SS; Cheshier SH
J Neurooncol; 2015 Jul; 123(3):449-57. PubMed ID: 25682090
[TBL] [Abstract][Full Text] [Related]
35. Immune Phenotype Correlates With Survival in Patients With GBM Treated With Standard Temozolomide-based Therapy and Immunotherapy.
Antonopoulos M; VAN Gool SW; Dionysiou D; Graf N; Stamatakos G
Anticancer Res; 2019 Apr; 39(4):2043-2051. PubMed ID: 30952748
[TBL] [Abstract][Full Text] [Related]
36. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
[TBL] [Abstract][Full Text] [Related]
37. Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.
Johanns TM; Dunn GP
Cancer J; 2017; 23(2):125-130. PubMed ID: 28410300
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
Sinnadurai M; McDonald KL
J Neurooncol; 2017 May; 132(3):359-372. PubMed ID: 28293764
[TBL] [Abstract][Full Text] [Related]
39. Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.
Poon CC; Sarkar S; Yong VW; Kelly JJP
Brain; 2017 Jun; 140(6):1548-1560. PubMed ID: 28334886
[TBL] [Abstract][Full Text] [Related]
40. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
